Fibrocell Science and Prothena have several 'shots on goal.'
A huge political headwind has been removed for this pharma.
The biotech has a great record growing earnings and shareholder value.
Coming up with a thesis from the five-minute chart.
The debate raging among investors about hepatitis C revenue declines.

Getting Defensive Now Real Money Pro($)

I am adding allocation to healthcare.
I would look to buy the weakness inside the $102.30-$100.59 zone.
Yesterday's action in the stock speaks volumes.
They are prone to being whipsawed by news.
Its hepatitis C drug will dominate the market.

Columnist Conversations

$600 million to buy market on close.
Much of what I'm hearing lately is the market is boring, it's a snooze-fest and nowhere is there a profit to b...
The Emini S&P 500 (e-SPM) and crude oil are following the same path today -- to the upside. In fact, the a...
On the weekly chart you can see the stock has recently tested a number of support lines and the 40 week (200 d...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.